ArticleFrontiers in pediatrics2025
Efficacy of lung surfactant combined with budesonide in improving bronchopulmonary dysplasia and growth of very low birth weight infants.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is few treatments for bronchopulmonary dysplasia (BPD), and systemic glucocorticoid therapy has serious side effects. Methods: Low birth weight infants were classified randomly into control group administered with pulmonary surfactant (200 mg/kg) and intervention group administered with pulmonary surfactant (200 mg/kg) and budesonide suspension (0.25 mg/kg) to explore the efficacy of combination of pulmonary surfactant and budesonide suspension is better than that of pulmonary surfactant alone. Results: The incidence of bronchopulmonary dysplasia was significantly lower in the intervention group (45%) compared to the control group (64%). Additionally, the duration of invasive ventilator use was significantly shorter in the intervention group (66.39 ± 37.09 h) than in the control group (82.05 ± 54.55 h); and the infants from the intervention group had a significantly shorter supplemental oxygen time, with the intervention group at 775.32 ± 396.06 h and the control group at 844.01 ± 414.18 h. Comparison of the basic conditions of the two groups of children showed no statistically significant differences in maternal medical history, gestational age, birth weight, sex, whether hormones were used prenatally, and delivery method ( Conclusion: Combination of pulmonary surfactant with budesonide suspension can significantly decrease the incidence of bronchopulmonary dysplasia in very low birth weight infants, reduce the duration of invasive mechanical ventilation, and promote earlier weaning from oxygen supplement. Clinical Trial Registration: Effect of budesonide combined with pulmonary surfactant on lung development in very low birth weight infants, ChiCTR2400086677, https://www.chictr.org.cn/showproj.html?proj=233373.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.